Caroline Mary

This inventor holds 22 USPTO granted patents and 18 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignees: Ose Immunotherapeutics, National Institute of Health and Medical Research, Effimune. Active years: 2014-2026.

USPTO Granted Patents = 22 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 38)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 33(Granted Patents)

Company Filing History:

20 out of 30

Ose Immunotherapeutics

patents

8 out of 1,853

National Institute of Health and Medical Research

The University of Nantes

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534533 - Anti-Chemokine Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications (2026-01-27),

2. 12448454 - Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof (2025-10-21),

3. 12371502 - Antibodies directed against CD127 (2025-07-29),

4. 12331118 - Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment (2025-06-17),

5. 12331115 - Uses of anti-SIRPg antibodies (2025-06-17),

6. 12252546 - Anti-SIRPa antibodies and their therapeutic applications (2025-03-18),

7. 11926671 - Antibodies and polypeptides directed against CD127 (2024-03-12),

8. 11884723 - Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies (2024-01-30),

9. 11713356 - Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer (2023-08-01),

10. 11440964 - Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody (2022-09-13),

11. 11352430 - Humanized anti-human-PD-1 antibody and its use in cancer treatment (2022-06-07),

12. 11279766 - Anti-SIRPa antibodies and their therapeutic applications (2022-03-22),

13. 11230602 - Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment (2022-01-25),

14. 11098128 - Antibodies and polypeptides directed against CD127 (2021-08-24),

15. 10689444 - Recombinant monovalent antibodies (2020-06-23),

Title: Innovator Spotlight: Caroline Mary – A Pioneer in Immunotherapy

Introduction: Caroline Mary, based in Sainte Pazanne, France, is an accomplished inventor recognized for her significant contributions to the field of immunotherapy. With an impressive portfolio of 19 patents, Caroline is at the forefront of developing novel therapies that harness the body's immune system to combat various diseases, including cancer.

Latest Patents: Among her most notable inventions are the humanized anti-human-PD-1 antibody and methods of using them for cancer treatment. This patent details the creation of humanized anti-PD-1 antibodies, along with the nucleic acids encoding such antibodies. The discovery focuses on enhancing immune responses by activating T cells, offering new hope in the treatment of cancer and infectious diseases. Another promising patent involves the uses of anti-SIRPg antibodies, which opens avenues for treating and preventing autoimmune disorders or diseases, marking another critical advancement in immunotherapy.

Career Highlights: Caroline's career has seen her collaborate with leading companies in the biomedical field, including Ose Immunotherapeutics and the Institut National de la Santé et de la Recherche Médicale. Her work within these institutions has greatly influenced innovative approaches to cancer treatment and immunotherapy.

Collaborations: Throughout her career, Caroline has engaged with esteemed colleagues such as Nicolas Poirier and Bernard Vanhove. Their collective expertise has contributed to her impactful research and developments in therapeutic methodologies.

Conclusion: Caroline Mary’s contributions through her patents not only illuminate the path for future innovations in cancer treatments but also establish her as a vital figure in the ongoing evolution of immunotherapy. Her relentless pursuit of advancements continues to inspire and shape the landscape of medical research.